Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Rheumatoid Arthritis
Interventions
DRUG

ACZ885 (investigational)

The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.

DRUG

Placebo

Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.

Trial Locations (4)

Unknown

Novartis Investigative site, Moscow

Novartis investigative site, Barcelona

Novartis Investigative site, Bern

Novartis investigative site, Istanbul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00504595 - Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter